Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results
Numinus Wellness Inc. (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q3 2025 financial results. The company achieved significant growth with revenue increasing 81.6% to $1.8 million compared to Q3 2024. Cedar Clinical Research operations saw a 95.8% revenue increase to $1.6 million, while Practitioner Training revenue grew by 12.3%.
The company demonstrated improved operational efficiency with gross margin reaching 48.2% compared to -4.6% in Q3 2024, and operating expenses decreased to $1.5 million from $3.8 million. The company ended Q3 with a cash balance of $822,835 and is working to revoke an ongoing cease trade order to relist on another exchange.
Numinus is strategically repositioning itself from a direct care provider to a comprehensive infrastructure provider for psychedelic medicine delivery, leveraging its experience of serving over 50,000 individuals across 200,000 appointments.
Numinus Wellness Inc. (OTCQB: NUMIF), azienda specializzata in terapie psichedeliche assistite per la salute mentale, ha comunicato i suoi risultati finanziari del terzo trimestre 2025. I ricavi sono cresciuti dell'81,6% raggiungendo 1,8 milioni di dollari rispetto al terzo trimestre 2024. Le attività di Cedar Clinical Research hanno registrato un aumento dei ricavi del 95,8% a 1,6 milioni, mentre i ricavi dalla formazione dei professionisti sono cresciuti del 12,3%.
L'azienda ha migliorato l'efficienza operativa, con un margine lordo al 48,2% rispetto al -4,6% del terzo trimestre 2024, e le spese operative sono scese a 1,5 milioni di dollari dai 3,8 milioni precedenti. Alla chiusura del trimestre la liquidità era di 822.835 dollari e la società sta lavorando per revocare un ordine di sospensione del trading in corso per essere quotata nuovamente su un altro mercato.
Numinus si sta riposizionando strategicamente: da fornitore diretto di servizi a fornitore di infrastrutture complete per l'erogazione di medicine psichedeliche, capitalizzando l'esperienza maturata con oltre 50.000 persone assistite e 200.000 appuntamenti.
Numinus Wellness Inc. (OTCQB: NUMIF), empresa dedicada a terapias asistidas con psicodélicos para la salud mental, informó sus resultados financieros del tercer trimestre de 2025. Los ingresos crecieron un 81,6% hasta 1,8 millones de dólares respecto al tercer trimestre de 2024. Las operaciones de Cedar Clinical Research aumentaron los ingresos un 95,8% hasta 1,6 millones, mientras que los ingresos por capacitación de profesionales crecieron un 12,3%.
La compañía mejoró la eficiencia operativa, con un margen bruto del 48,2% frente al -4,6% del tercer trimestre de 2024, y los gastos operativos disminuyeron a 1,5 millones de dólares desde 3,8 millones. Al cierre del trimestre contaba con un saldo de efectivo de 822.835 dólares y está gestionando la revocación de una orden de suspensión de cotización para volver a listarse en otra bolsa.
Numinus se está reposicionando estratégicamente, pasando de proveedor directo de atención a ofrecer una infraestructura integral para la administración de medicinas psicodélicas, apoyándose en su experiencia atendiendo a más de 50.000 personas en 200.000 citas.
Numinus Wellness Inc. (OTCQB: NUMIF), 정신 건강 분야의 심리활성제 보조 치료를 전문으로 하는 기업이 2025년 3분기 재무실적을 발표했습니다. 매출은 전년 동기 대비 81.6% 증가한 180만 달러를 기록했습니다. Cedar Clinical Research 사업부는 매출이 95.8% 증가해 160만 달러를 기록했고, 실무자 교육 매출은 12.3% 증가했습니다.
회사는 영업 효율성도 개선되어 매출총이익률이 전년 동기 -4.6%에서 48.2%로 개선되었고, 영업비용은 기존 380만 달러에서 150만 달러로 감소했습니다. 3분기 말 현금 잔액은 822,835달러였으며, 다른 거래소에 재상장하기 위해 현재 발효 중인 거래정지 명령의 해제를 추진 중입니다.
Numinus는 직접 진료 제공자에서 심리활성제 의료 제공을 위한 종합 인프라 제공자로 전략적 전환을 진행하고 있으며, 50,000명 이상의 환자와 200,000건의 예약을 지원한 경험을 기반으로 하고 있습니다.
Numinus Wellness Inc. (OTCQB: NUMIF), société spécialisée dans les thérapies assistées par substances psychédéliques pour la santé mentale, a publié ses résultats financiers du troisième trimestre 2025. Le chiffre d'affaires a augmenté de 81,6% pour atteindre 1,8 million de dollars par rapport au T3 2024. Les activités de Cedar Clinical Research ont vu leurs revenus progresser de 95,8% à 1,6 million, tandis que les revenus issus de la formation des praticiens ont augmenté de 12,3%.
L'entreprise a amélioré son efficience opérationnelle, avec une marge brute atteignant 48,2% contre -4,6% au T3 2024, et les charges d'exploitation ont diminué à 1,5 million de dollars contre 3,8 millions. À la clôture du trimestre, la trésorerie s'élevait à 822 835 dollars et la société s'emploie à faire lever une ordonnance de suspension de négociation en cours afin d'être réinscrite sur une autre bourse.
Numinus se repositionne stratégiquement, passant d'un fournisseur de soins directs à un fournisseur d'infrastructures complet pour la délivrance de médicaments psychédéliques, en capitalisant sur son expérience auprès de plus de 50 000 personnes et 200 000 rendez-vous.
Numinus Wellness Inc. (OTCQB: NUMIF), ein Unternehmen, das sich auf psychedelisch unterstützte Therapien im Bereich der psychischen Gesundheit spezialisiert hat, veröffentlichte seine Finanzergebnisse für das dritte Quartal 2025. Der Umsatz stieg im Vergleich zum dritten Quartal 2024 um 81,6% auf 1,8 Millionen US-Dollar. Die Tätigkeiten von Cedar Clinical Research verzeichneten einen Umsatzanstieg von 95,8% auf 1,6 Millionen, während die Umsätze aus der Ausbilderweiterbildung um 12,3% wuchsen.
Das Unternehmen verbesserte die operative Effizienz: die Bruttomarge erreichte 48,2% gegenüber -4,6% im Q3 2024, und die operativen Aufwendungen sanken von 3,8 Millionen auf 1,5 Millionen US-Dollar. Zum Ende des Quartals verfügte das Unternehmen über einen Kassenbestand von 822.835 US-Dollar und arbeitet daran, eine laufende Handelssperre aufzuheben, um an einer anderen Börse neu gelistet zu werden.
Numinus positioniert sich strategisch neu – weg vom direkten Versorger hin zum umfassenden Infrastruktur-Anbieter für die Bereitstellung psychedelischer Medizin – und baut dabei auf die Erfahrung aus der Betreuung von über 50.000 Personen in 200.000 Terminen.
- Revenue increased significantly by 81.6% to $1.8 million in Q3 2025
- Cedar Clinical Research revenue grew 95.8% to $1.6 million
- Gross margin improved substantially to 48.2% from -4.6% year-over-year
- Operating expenses reduced by 59.8% to $1.5 million through cost containment initiatives
- Net loss decreased significantly from $5.77 million to $741,575
- Low cash balance of $822,835 at quarter end
- Company currently under cease trade order
- Low shareholder meeting participation with only 20.49% of shares represented
All financial results are reported in Canadian dollars unless otherwise stated.
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended May 31, 2025 ("Q3 2025 ").
"The progress we are making in fiscal 2025 demonstrates our success in shifting to a leaner operating model that will enable future growth," said Michael Tan, CEO of Numinus. "With a solid operational platform in place, Numinus is entering the next phase of its evolution: from direct care provider to the backbone of in-clinic delivery for approved psychedelic medicines."
"The Company is now up to date with its public company filing requirements and will be moving forward with its application to revoke the ongoing cease trade order," added Kelvin Yang, CFO of Numinus. "Once the cease trade order has been lifted, the Company will seek to relist on another reputable exchange."
Revenue from continuing operations
The Company's consolidated revenues increased by
Revenues from Cedar Clinical Research ("CCR") operations during Q3 2025 increased by
Revenues from Practitioner Training during Q3 2025 increased by
Gross margin in Q3 2025 was
Operating expenditures
Operating expenditures and other items were
Balance Sheet and Liquidity
Numinus ended the quarter with a cash balance of
Q3 2025 Performance Metrics
| For the quarter ended: | |||
| May 31, 2025 (Q3 2025) | May 31, 2024 (Q3 2024) | % change | |
| Total Revenue | |||
| Cost of revenue | 932,842 | 1,038,887 | - |
| Gross Profit (Loss) | ( | -n/a | |
| Gross profit margin (loss) | ( | 528 bps | |
| Operating expenses and other items | 1,538,914 | 3,833,482 | - |
| Loss and comprehensive loss | ( | ( | n/a |
Numinus' unaudited condensed consolidated interim financial statements for the three months ended May 31, 2025, and related management's discussion and analysis are available on Numinus' Investor Relations website at www.investors.numinusnetwork.com and under the Company's profile on SEDAR+ at www.sedarplus.ca. These documents were prepared in accordance with IFRS.
Outlook
With strong relationships with leading drug sponsors and deep experience running late-stage clinical trials, Numinus is well-positioned as the bridge between regulatory approval and the rollout of thousands of clinics preparing to offer psychedelic-assisted therapy.
The company's focus going forward will be on building the infrastructure these clinics will need. Leveraging Numinus' operational expertise, extensive clinical dataset, and sector relationships, we are developing technology-enabled solutions to streamline insurance reimbursement, integrate measurement-based care, standardize therapist credentialing, and ensure compliance. These are essential capabilities for scaling psychedelic therapies safely and effectively, and Numinus is uniquely positioned to deliver them.
Numinus' foundation rests on two growing business units: Cedar Clinical Research and Numinus Practitioner Training. This, combined with valuable intellectual property and one of the most comprehensive sets of protocols and procedures in the sector, which was built through serving over 50,000 individuals and delivering 200,000 appointments, provides Numinus with unmatched insight into what it will take to operationalize psychedelic therapies at scale.
Momentum in the sector is accelerating. Multiple drug candidates are approaching regulatory submission, and supportive policy initiatives are gaining traction at both the federal and state levels. This growing demand, combined with Numinus' operational readiness, positions us to capitalize on the market opportunity as these treatments transition from trials to clinics.
Numinus is focused, growing, and strategically positioned to be a critical enabler of the psychedelic therapy rollout. The goal is to provide the systems, infrastructure, and expertise that will bring these treatments from approval to the patients who need them most.
Voting Results from the Annual General and Special Meeting Held on Thursday, August 28, 2025
A total of 65,684,359 common shares representing
The following four nominees proposed by Numinus were elected as directors of Numinus to serve until Numinus' next annual meeting of shareholders, or until their successors are elected or appointed. Below is a summary of the voting results for the directors elected:
| DIRECTOR | VOTES CAST FOR | % VOTES FOR | VOTES WITHHELD | % VOTES WITHHELD |
| Payton Nyquvest | 32,208,565 | 6,842,849 | ||
| Larry Timlick | 37,067,331 | 1,984,083 | ||
| Michael Tan | 33,515,358 | 5,536,056 | ||
| Donna Wilson | 37,305,639 | 1,745,775 |
In addition to the election of all nominees listed as directors in the management information circular, dated July 29, 2025 (the "Circular"), Numinus shareholders approved all other resolutions placed before the Meeting. More information about the resolutions voted on at the Meeting is available is available in Numinus' Management Information Circular, which can be found on the Company's profile on SEDAR+ at www.sedarplus.ca. Final voting results on all matters voted on at the Meeting are also filed on SEDAR+.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
SOURCE Numinus Wellness Inc.
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, ability of Numinus to maintain or increase earnings; ability of Numinus to achieve or maintain profitability; results of changes to operations from a financial or business perspective; the effect of cost containment measures on Numinus business and financial position; changes to cash burn rate, expenses, corporate programs or priorities, or unanticipated costs affecting cash runway or the pathway to positive cashflow or profitability, the effect of any transaction or other activity undertaken by the company in connection with the strategic review; interest in, uptake of and the ability to commercialize the Numinus Training; dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, if any, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers; and other risk factors set forth in our annual information form dated July 25, 2025 and available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.
For more information:
Investor Contact
Craig MacPhail
invest@numinusnetwork.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264825
FAQ
What were Numinus Wellness (NUMIF) Q3 2025 revenue and growth?
How much did Numinus (NUMIF) reduce its operating expenses in Q3 2025?
What is Numinus Wellness's (NUMIF) new strategic direction?
What was Numinus's (NUMIF) gross margin in Q3 2025?
How much cash does Numinus (NUMIF) have on its balance sheet?
